SCHEDULE: CRISPR Therapeutics: Investment Managers Disclose Stake

Orbis Investment Management and Allan Gray Australia report a combined 5.6% beneficial ownership in CRISPR Therapeutics AG.

Summary

• Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed a Schedule 13G, indicating their beneficial ownership of CRISPR Therapeutics AG common stock.
• The total aggregate amount beneficially owned by these reporting persons is 5,449,161 shares.
• This represents 5.6% of the class of securities.
• Orbis Investment Management Ltd holds 5,433,344 shares with sole voting and dispositive power.
• Allan Gray Australia Pty Ltd holds 15,817 shares with sole voting and dispositive power.
• Both entities are classified as non-U.S. institutions equivalent to Investment Advisers.
• They certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily indicating a significant but not controlling stake by investment managers, with no immediate red flags but also no strong positive catalysts.

Positives

• Significant investment by established financial entities (Orbis Investment Management and Allan Gray Australia) suggests confidence in CRISPR Therapeutics' long-term prospects.
• The reporting persons are classified as Investment Advisers, implying a professional and strategic investment approach.
• The filing confirms that the shares are held in the ordinary course of business, not for hostile takeover or control purposes.

Negatives

• The filing does not provide specific details on the 'other persons' who have the right to receive dividends or proceeds from the sale of securities held by Orbis Investment Management and Allan Gray Australia, which could obscure ultimate beneficial ownership.
• The filing is an amendment (Amendment No. 3), suggesting ongoing adjustments to holdings or reporting, though the specific reasons for the amendment are not detailed here.

Risks

• While not explicitly stated as a risk in this filing, any significant shift in holdings by these large investors could impact share price.
• The nature of the 'other persons' mentioned in Item 6 could represent a concentration of beneficial ownership that is not fully transparent.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from CRISPR Therapeutics AG. It solely reports on the ownership stake of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd.

Management Comments

• Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that CRISPR Therapeutics AG operates in the rapidly evolving and highly competitive gene editing and biotechnology sector. Significant stakes held by investment management firms in such companies often reflect a belief in the long-term potential of their technology and therapeutic pipeline, but also highlight the speculative nature and inherent risks associated with early-stage biotechnology investments.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by institutional investors may be viewed positively, potentially indicating confidence in the company's future. However, it also means a larger portion of shares are held by entities that may trade actively.
• Management: The filing confirms that the reporting persons are not seeking to influence control, which may provide some stability for current management.
• Creditors/Suppliers: No direct impact is indicated by this filing.

Next Steps

• Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd will continue to hold and potentially adjust their beneficial ownership of CRISPR Therapeutics AG shares.
• The Commission staff may request further information regarding the beneficial ownership as per the certification.

Key Dates

Keywords

CRISPR Therapeutics, Schedule 13G, Orbis Investment Management, Allan Gray Australia, Beneficial Ownership, Investment Adviser, Gene Editing